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1444YAP in tumorigenesis: Friend or foe?experimental and clinical research is paramount to explore the
complicated relationship between YAP and tumorigenesis before
YAP has been considered as a novel therapeutic target.
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We read with great interest the recent Journal of Hepatology
article published by Perra et al. [1]. The authors proved that
yes-associated protein (YAP) accumulated in early preneoplastic
lesions and oval cells in the resistant-hepatocyte rat model and
in early dysplastic nodules and adenomas in human, respectively.
Moreover, verteporﬁn which disrupted the formation of
YAP-TEAD complex was proven to decrease the accumulation of
YAP. It seemed that YAP was a pernicious factor in an experimen-
tal model or in humans with tumors. Thus, they highlighted the
synchronous relationship between YAP and liver tumorigenesis
and the function of YAP used as a therapeutic target in liver
cancer.
We want to point out that in contradiction to the data by
Perra et al., Wang et al. [2] showed that YAP could inhibit the
growth of human malignant cells via apoptosis by the activation
of the p73 pathway. In addition, PML is another tumor suppressor
pathway in collaboration with YAP, it can interact with YAP-1
and enhance the stabilization of YAP-1 [3]. In another article,
Bertini et al. [4] also demonstrated that YAP-1 associated with
p73 and increased the stability of p73 to induce apoptosis
involved in YAP. Moreover, research conducted by Strano et al.
[5] revealed that the WW domains of YAP interacted only with
the member of the p53 family which had a PPXY motif. The
principle of sequence-speciﬁc protein–protein interaction
determined that p73c, a p73 isoform, could not interact with
YAP, although the overexpression of YAP increased the p73a
transcription. In conclusion, YAP has the dual function of
inhibition and promotion in oncogenesis, depending on the speci-
ﬁc tissues or cancer types. In addition, it is necessary to study the
molecular partners related to YAP before YAP targeting therapy is
further developed.
In addition to the relationship between YAP and the growth of
cancer, another report investigated the relationship between YAP
and chemosensitivity in hepatocellular carcinoma cells. Bai et al.
[6] found that YAP increased chemosensitivity of HepG2 cells by
modulating p53 and both TEAD and WW domains were neces-
sary for the function of p53 mediated by YAP. Furthermore, p53
could positively feedback to control YAP expression via interact-
ing with the promoter of YAP. Moreover, the articles by Ehsanian
et al. [7] and Yuan et al. [8] pointed out that YAP acted as a tumor
suppressor in head and neck cancer and breast cancer. A further
study found that YAP-1 had the ability to promote anoikis and
inhibit the metastasis in breast cancer [9].
In conclusion, YAP can produce both beneﬁcial and detrimen-
tal effects in the growth of malignant cells. It has been conﬁrmed
to play contradictory roles in tumorigenesis. Therefore, more
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